Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A dose-escalating, dose-ranging study of the safety, tolerability, and immunogenicity of a bivalent influenza peptide conjugate vaccine formulated with aluminum- and iscomatrix containing adjuvants (BIPCV/IMX) evaluated in healthy adults 18 to 35 years of age.

Next Previous
X
Search
Trial Profile

A dose-escalating, dose-ranging study of the safety, tolerability, and immunogenicity of a bivalent influenza peptide conjugate vaccine formulated with aluminum- and iscomatrix containing adjuvants (BIPCV/IMX) evaluated in healthy adults 18 to 35 years of age.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 May 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs V 512 (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; First in man; Pharmacodynamics
  • Sponsors Merck Sharp & Dohme Corp.

    • Most Recent Events

    • 04 Nov 2009 Planned number of patients changed from 241 to 187 as reported by ClinicalTrials.gov
    • 04 Nov 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
    • 23 Feb 2009 New source identified and integrated (ClinicalTrials.gov): study phase identified and status updated to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top